Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Solvonis Therapeutics ( (GB:SVNS) ) has shared an announcement.
Solvonis Therapeutics has announced a corporate restructuring to streamline its operations and focus on research and development. This includes the reorganization of its subsidiaries in Ireland, the UK, and the US, and the disposal of a non-core subsidiary, Graft Polymer IP Limited, to consolidate intellectual property and enhance R&D capabilities. The company also issued new shares to settle historical liabilities and granted share options to its CEO and non-executive directors, reflecting its commitment to strategic transformation and stakeholder alignment.
More about Solvonis Therapeutics
Solvonis Therapeutics plc is an emerging biopharmaceutical company focused on developing novel small-molecule therapeutics for central nervous system (CNS) disorders. Headquartered in London and listed on the London Stock Exchange, Solvonis is advancing a pipeline of repurposed and novel compounds targeting addiction, psychiatry, and neurology, with lead programs addressing Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD).
Average Trading Volume: 66,563,279
Technical Sentiment Signal: Buy
Current Market Cap: £21.7M
Learn more about SVNS stock on TipRanks’ Stock Analysis page.